Sandrine MillerMontgomery, Pharm.D., Ph.D, is the Cofounder, President and CEO of Micronoma, the first cancerdetection company utilizing signals from microbial nucleic acids, to empower clinicians to diagnose cancer at an early stage with minimally invasive, microbiomedriven liquid biopsy technology. Before cofounding Micronoma, she was executive director of UC San Diegos Center for Microbiome Innovation (CMI), which she coled with renowned microbiome researcher, Dr. Rob Knight. Sandrine established a worldclass team focused on expanding industry and academic collaborations in the field of microbiome research that resulted in raising more than tens of millions of dollars of financial support through key partnerships toward application of this science to AI, diet and nutrition, aging, environment, human disease understanding and more. Sandrine has a talent for assembling efficient and successful teams around innovative products as shown by her work at Helixis, acquired by Illumina, and Mo Bio Labs acquired by QIAGEN.
Microbiome driven liquid biopsy for lung cancer detection
Recent clinical validity data of OncobiotaLUNGdetect on two independent cohorts will be presented. This assay has been developed to detect lung cancer even in its earliest stages (I and II), utilizing multiomics technology, including circulating tumor microbial DNA (ctmbDNA) analyzed by nextgen sequencing, and AI to provide results with greatspecificity and sensitivity.